Solubilization of protein BM-40 from a basement membrane tumor with cheating agents and evidence for its identity with osteonectin and SPARC  by Mann, Karlheinz et al.
Volume 218, number 1, 167-172 FEB 04818 June 1987 
Solubilization of protein BM-40 from a basement 
membrane tumor with chelating agents and evidence for its 
identity with osteonectin and SPARC 
Karlheinz Mann,  Rainer  Deutzmann,  Mats  Paulsson* and Rupert  T impl 
Max-Planck-lnstitut f~r Biochemie, D-8033 Martinsried, FRG 
Received 6April 1987; revised version received 24 April 1987 
Up to 80% of the calcium-binding protein BM-40 could be extracted from a tumor basement membrane 
with a physiological buffer containing 10 mM EDTA. About half of its amino acid sequence was determined 
by Edman degradation demonstrating identity with cDNA deduced sequences of bone osteonectin and 
SPARC. 
Extracellular matrix; Ca z ÷-binding protein; Amino acid sequence; Proteolytic fragment 
1. INTRODUCTION 
Basement membranes are unique extracellular 
protein matrices with a broad tissue distribution. 
They are composed of coUagenous protein, several 
proteoglycans and a diverse group of other 
glycoproteins which are still incompletely 
characterized [1]. Among the latter components i
also a small protein BM-40 which has recently been 
purified from 6 M guanidine-HCl extracts of the 
mouse Engelbreth-Holm-Swarm (EHS) tumor [2]. 
The protein consists of a single, disulfide-bonded 
polypeptide chain which is partially cleaved by en- 
dogenous proteases during purification. Im- 
munological assays failed to show any relationship 
to other known basement membrane proteins and 
demonstrated the widespread occurrence of BM-40 
in cell cultures and tissue extracts. It was also pre- 
sent in authentic basement membranes such as lens 
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capsule and Reichert's membrane. During the 
characterization f BM-40 [2] we noticed a possi- 
ble relationship to a serum albumin-binding pro- 
tein obtained from endothelial and other cell 
cultures [3,4] which was later named SPARC and 
characterized by a complete amino acid sequence 
deduced from murine cDNA clones [5]. An almost 
identical sequence was recently determined for 
bovine bone osteonectin (M. Bolander, personal 
communication) which is known as a calcium- 
binding protein [6,7]. 
The data suggested that calcium-binding pro- 
teins are present in basement membranes and con- 
tribute to their special architecture. Evidence for 
this possibility came initially from the findings that 
laminin polymerizes in the presence of calcium [8] 
and that extracts of the EHS tumor obtained with 
10 mM EDTA in physiological buffer contain 
large amounts of the laminin-nidogen complex [9]. 
In the present study we have applied the same ex- 
traction procedure for the purification of BM-40 in 
a more gentle manner than done before. Partial 
amino acid sequence analysis provided strong 
evidence that BM-40 is identical with SPARC and 
osteonectin. 
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2. MATERIALS AND METHODS 
Aliquots (75 g) of EHS tumor were briefly 
homogenized in 1.5 and 0.8 1 of 0.15 M NaCI, 
0.05 M Tris-HCl, pH 7.4, containing 2 mM 
phenylmethanesulfonyl fluoride (PMSF) and 
2 mM N-ethylmaleimide (NEM) as protease in- 
hibitors (TBS) and centrifuged. The remaining 
residue was extracted twice with 375 ml TBS sup- 
plemented with 10 mM EDTA by stirring for 1 h 
at 4°C [9]. Subsequent extracts were obtained with 
200 ml of 2 M and 6 M guanidine. HCI containing 
protease inhibitors (each for 1 day, 4°C). Aliquots 
(100 ml) of the first TBS-EDTA extract were 
passed over a Sepharose CI-6B column (3.2 x 
134 cm) equilibrated in TBS with 2 mM EDTA, 
0.5 mM PMSF and 0.5 mM NEM. Fractions con- 
taining BM-40 were pooled from four runs, con- 
centrated to 200 ml over an Amicon PM10 filter 
and dialyzed for 1 day at 4°C against 2 × 4 1 of 
2 M urea, 0.05 M Tris-HC1, pH 8.6, containing 
protease inhibitors. They were then passed over a 
DEAE-cellulose column (2 x 20 cm) equilibrated 
in the same solvent and bound protein was eluted 
with a linear NaCI gradient (0-0.4 M NaCI, 
800-1000 ml). Final purification of BM-40 was 
achieved on a Sephacryl S-200 column (1.5 × 
105 cm) equilibrated in 0.2 M ammonium bicar- 
bonate. 
In an alternative procedure 360 ml of the TBS- 
EDTA extract were mixed with 120 ml of 8 M urea 
and passed over a DEAE-cellulose column (3 x 
25 cm) equilibrated in the same mixture of solvents 
followed by elution with a linear gradient (total 
1000 ml) up to 0.6 M NaCI dissolved in the buffer. 
Further purification steps included chromatogra- 
phy on Sephacryl S-200 and DEAE-cellulose at pH 
8.6 as described above. In addition, BM-40 was 
purified from 6 M guanidine.HCl extracts as 
described [2]. 
Cleavage of BM-40 dissolved in 0.15 M NaCI, 
0.05 M Tris-HCl, pH 7.4, 2 mM CaCI2 by SV8 
protease was performed at an enzyme-substrate 
ratio of 1:100 for 24 h at 37°C. Other samples 
were reduced with 2 mM dithioerythritol in 0.1 M 
Tris-HCl, pH 8.5, 6 M guanidine-HC1, S- 
carboxymethylated and cleaved in 0.2 M am- 
monium bicarbonate with TPCK-trypsin (24 h, 
37°C). Peptides were separated on a Sephadex 
G75sf column (1.5 x 120 cm) in 0.2 M ammonium 
bicarbonate and/or by HPLC on a reversed-phase 
RP 318 column (Biorad, Munich) equilibrated in 
0.107o trifluoroacetic acid and eluted with 
acetonitrile gradients. 
Proteins and fragments were characterized by 
SDS-polyacrylamide gel electrophoresis [20] in 
5-15070 gradient slab gels and after hydrolysis with 
6 M HCI (24 h, 110°C) by amino acid analysis on 
a Biotronik LC 5001 analyzer. Quantitative deter- 
minations of BM-40 were carried out by the 
radioimmuno-inhibition assay [2]. Edman degra- 
dation of samples (0.1-1 nmol) was performed in 
a gas-phase (model 470A, Applied Biosystems) or 
a spinning-cup liquid-phase sequencer (model 
890 C, Beckman). Released amino acid derivatives 
were identified and quantitated by HPLC follow- 
ing the manufacturer's recommendation r by us- 
ing an isocratic HPLC system [11]. 
3. RESULTS 
We have recently developed a fast and gentle ex- 
traction protocol for the EHS tumor basement 
membrane matrix which allowed the purification 
of large quantities of the laminin-nidogen complex 
[9]. The same extracts when examined by radioim- 
munoassay contained also substantial amounts of 
BM-40 (table 1). Brief homogenization of the 
tumor in TBS releases about 20°70 of this protein 
while about 8007o is solubilized by subsequent ex- 
Table 1 
Solubilization of BM-40 by sequential extraction of the 
EHS tumor 
Extract Amount of 
BM-40 
1. 0.05 M Tris-HC1, pH 7.4, 0.15 M 
NaCI (TBS) 107 ___ 34 
2. TBS 30 + 12 
3. TBS, 10 mM EDTA 352 + 93 
4. TBS, 10 mM EDTA 31 _+ 27 
5. 2 M guanidine. HC1 5 _+ 2 
6. 6 M guanidine-HCI 9 + 6 
Sum 534 + 108 
Yields (/zg/g wet tumor) were determined by 
radioimmunoassay nd are given as average values 
(+_ SD) of 4 experiments 
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Fig.1. Initial chromatographic steps in the purification 
of BM-40 from TBS-EDTA extracts of the EHS tumor. 
(a) Passage of 100 ml extract over Sepharose C1-6B 
column (3.2 x 134 cm); (b) chromatography of four 
BM-40 pools after step a on DEAE-cellulose in 2 M 
urea, 0.05 M Tris-HC1, pH 8.6, and elution with a 
gradient from 0-0.4 M NaCI (1 1); (c) chromatography 
of 360 ml TBS-EDTA extract on DEAE-cellulose in 2 M 
urea, 0.11 M NaCI, 0.038 M Tris-HC1, pH 7.4, followed 
by a 1 1 gradient up to 0.6 M NaCI. Runs were 
monitored for absorbance at280 nm( ) and BM-40 
content (o---o) measured in aliquots of individual 
fractions by radioimmunoassay. Horizontal bars denote 
pools containing laminin-nidogen complex (LN), BM-40 
and heparan sulfate proteoglycan (PG). Arrows indicate 
start of the gradient. 
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Fig.2. Comparison of BM-40 purified from TBS-EDTA 
extracts (lane 1) and from 6 M guanidine-HCI extracts 
(lane 2) and a SV8 protease digest (lane 3) by SDS- 
polyacrylamide gel electrophoresis. Samples were 
analyzed non-reduced ( - )  or after reduction with 
2-mercaptoethanol (+). Numbers on each site indicate 
the migration position of globular marker proteins 
(Mr x 10-3). 
traction with TBS containing 10 mM EDTA. Fur- 
ther extractions with concentrated guanidine. HC1 
solutions as have been used before in the purifica- 
tion of BM-40 [2] released only insignificant 
amounts of the protein (table 1). The total yield of 
BM-40 solubilized by the new extraction scheme 
was about 2-fold higher than those reported in [2]. 
The TBS-EDTA extracts were the most conve- 
nient source for the purification of BM-40 and 
contained BM-40 in a 4-fold molar excess com- 
pared to laminin-nidogen (table 1 [9]). Both com- 
ponents could be easily separated from each other 
by molecular sieve chromatography on agarose 
(fig.la). Further purification of BM-40 was 
achieved by chromatography on DEAE-cellulose 
(fig. lb) followed by a final step on Sephacryl S-200 
(not shown). The protein showed a major band in 
electrophoresis identical in mobility to BM-40 ob- 
tained by the previous procedure (fig.2) 
Table 2 
Comparison of the amino acid composition of BM-40 
with that of SPARC deduced from cDNA sequence [5] 
BM-40 SPARC 
(residues/peptide) 
Aspartic acid 34.0 33 a 
Threonine 17.2 17 
Serine 9.6 7 
Glutamic acid 47.6 46 b 
Proline 16.4 17 
Glycine 16.8 15 
Alanine 15.1 14 
Half cysteine 11. Ic 14 
Valine 18.9 20 
Methionine 2.3 5 
Isoleucine 11.0 12 
Leucine 23.9 24 
Tyrosine 6.7 7 
Phenylalanine 12.5 12 
Histidine 12.2 12 
Lysine 18.3 19 
Arginine 8.4 8 
Tryptophan n.d. 3 
Sum 282.0 285 
a Plus asparagine 
b Plus glutamine 
c Determined as S-carboxymethyl c steine 
n.d., not determined 
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demonstrating a purity of > 95°7o. An alternative 
purification procedure was based on initial 
chromatography of TBS-EDTA extracts on 
DEAE-cellulose which also separated BM-40 from 
the laminin-nidogen complex and from pro- 
teoglycans (fig.lc) and allowed the processing of 
larger amounts of material. The final products ob- 
tained by both procedures were of equivalent puri- 
ty and were obtained in yields of 2-3  mg BM-40 
from 100 g wet tumor tissue. 
The amino acid composition of BM-40 obtained 
from TBS-EDTA extracts (table 2) was com- 
parable to that reported before for BM-40 obtain- 
ed by extraction with 6 M guanidine. HCI [2]. A 
remarkable difference was observed in the extent 
of polypeptide cleavage due to endogenous pro- 
teolysis which results in two disulfide-linked 
fragments comprising about 75 and 25% of the 
mass of BM-40, respectively. This cleavage was 
nearly complete for guanidine-extracted but only 
in the order of 20-30°7o for the EDTA-extracted 
protein (fig.2). In circular dichroism studies, the 
latter material showed about 30°70 o~-helix which 
was reduced considerably after treatment with 
guanidine (Engel, J., personal communication). 
Together the data demonstrate that extraction of 
BM-40 with TBS-10 mM EDTA results in a more 
intact form of the protein than obtained 
previously. 
Purified BM-40 corresponds with a few excep- 
tions (Ser, Cys, Met) in its amino acid composi- 
tion, within the limits of analytical error (__ 10o70), 
to the composition predicted for SPARC (table 2) 
from eDNA sequences [5]. Determination of 53o/o 
of the sequence of BM-40 by Edman degradation 
(table 3) revealed so far no difference from 
SPARC confirming the very likely identity of both 
proteins. The major N-terminal sequence of 
BM-40 (APQQ) was also identical to that reported 
for bovine osteonectin [7,12]. A minor N-terminal 
sequence apparently corresponds to the en- 
dogenous cleavage site (fig.2) and located this site 
at a Leu-Leu bond in position 197/198 of SPARC. 
Further sequence data were obtained from pro- 
teolytic fragments of BM-40 primarily generated 
by cleaving the non-reduced protein with SV8 pro- 
tease. This digestion produced a large, disulfide- 
bonded fragment SPI with about half the mass of 
BM-40 (fig.2) which could be separated from 
smaller peptides on Sephadex G75sf. This frag- 
ment contained two new major N-terminal se- 
quences demonstrating the presence of two 
disulfide-linked chain fragments and in addition a 
minor sequence due to a partial cleavage within the 
Table 3 
Partial amino acid sequences of BM-40 
Component a Sequence Position in 
SPARC b 
BM-40 a: APQQTEV AEE I  VEEETVVEE 1- 20 
b: LAXDFEK NYNMYI  FPVHWQF 198-217 
Fragment SPI a: VVADNPX QNHH 48- 58 
b: LAP  LRAP L I PME 234-245 
m:GTKKGHK(L)HL  D Y 116-127 
Fragment SP2 a: TCDLDND KY I  ALE  254-266 
b: WAGCFGI  K E 268-276 
Fragment SP3 QHPI  DGY L S HTE 222-233 
Fragment SP4 QDI  NKDL V I 277-285 
Fragment SP5 KQKLRVK K I HE 173-183 
Fragment T6 LHLDYI  G P CK 123-132 
FragmentT7 YI  APCLD S ELTEFPLR 133-148 
Fragment T8 D WL K 151-154 
a Sequences of components with several chain fragments are classified as major (a,b) or minor (m, 
20-30% of a,b) sequences according to the yields of PTH derivatives. Assignment of positions 
in cases of two major sequences was done according to the known SPARC sequence [5] 
b Numbering according to [5] without signal peptide (total 285 amino acid residues) 
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larger chain. Another fragment SP2 also consisted 
of two chain fragments which are apparently con- 
nected by the last two cysteine residues found in 
the SPARC sequence [5]. All those cleavage sites 
are preceded in the SPARC sequence by a Glu 
residue [5] as expected from the specificity of the 
protease [13]. Several more sequences were deter- 
mined for some smaller peptides obtained by 
cleavage with SV8 protease (including the C- 
terminal peptide SP4) and by cleavage of reduced 
BM-40 with trypsin (table 3). 
4. DISCUSSION 
The data so far leave no doubts that mouse 
BM-40, mouse SPARC [5] and bovine osteonectin 
(Bolander, M., personal communication) are prod- 
ucts of the same gene or at least very similar genes. 
The osteonectin sequence shows 92°7o homology to 
SPARC with substantial differences in the first 20 
amino acid residues and an additional Cys residue 
located between position 191/192 of SPARC. Both 
sequences are, however, similar in domain struc- 
ture starting with a region of rather acidic nature 
( -50 residues), followed by a disulfide-bonded do- 
main (11 Cys; -90  residues), a Cys-free region 
(-100 residues) and a second disulfide-bonded 
region (3 Cys; -40  residues). Our sequence data on 
BM-40 fragments are compatible with a covalent 
connection between both disulfide-bonded o- 
mains as predicted from the presence of 14 Cys 
residues in SPARC [5]. This indicates that frag- 
ment SP 1 of BM-40 contains two segments encom- 
passing positions 48-140 and 234-253, 
respectively. The last two cysteine residues form, 
however, a separate loop as shown by sequence 
analysis of peptide SP2. How the extra cysteine 
residue found in bovine osteonectin can be accom- 
modated in this arrangement remains at the mo- 
ment an open question. 
The rather selective xtraction of BM-40 with 
physiological buffer containing EDTA suggests 
that calcium-binding changes its affinity for other 
components within the tumor basement mem- 
brane. It is in this context noteworthy that the 
same extraction procedure also solubilizes ubstan- 
tial amounts of laminin and nidogen [9] indicating 
the possible xistence of complexes between BM-40 
and these proteins. A distinct loss of re-helical 
structures has been observed after removal of 
calcium from BM-40 (Engel, J., personal com- 
munication) which could be a factor in changing 
the interaction potential for other matrix com- 
ponents. 
BM-40 has not only been detected as a compo- 
nent of the EHS tumor but is also present in lens 
capsule, Reichert's membrane and various other 
tissue extracts and cell cultures [2]. This agrees 
with similar observations on the widespread 
distribution of SPARC mRNA [14] and the fre- 
quent finding that osteonectin s produced not only 
by bone but also by several other cells [13,15-17]. 
The data demonstrate that this unique calcium- 
binding protein identified as osteonectin, SPARC 
or BM-40 is in fact a frequent constituent of 
mineralizing and non-mineralizing connective 
tissues and of basement membranes suggesting a
rather general biological role. It is likely that some 
of its functions are related to calcium-binding 
which still remain to be established. 
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